Pharmacokinetics of ingested xenobiotics in children: A comparison with adults

2.50
Hdl Handle:
http://hdl.handle.net/10029/9261
Title:
Pharmacokinetics of ingested xenobiotics in children: A comparison with adults
Authors:
Zwart LL de; Haenen HEMG; Versantvoort CHM; Sips AJAM
Other Titles:
Farmacokinetiek van orale xenobiotica in kinderen: Een vergelijking met volwassenen
Abstract:
Both in the development of medicinal products as well as in risk assessment of other xenobiotics there is an increasing awareness that children should be considered as a special group. Children are exposed to other doses than adults and the pharmacokinetics and pharmacodynamics can be very different in children and adults. In general it can be concluded that the effects of age on pharmacokinetics are most pronounced during the first 6-12 months of life. Full adjustment of dosing or TDI's for pharmacokinetic differences can relatively easily be applied and should, to our opinion be seen as a first step in considering risk for the paediatric population. For risk assessment for drugs as well as for other xenobiotics, it seems to be essential that young animal models will be used for determining NOAELs, that are relevant for the paediatric population. The use of a paediatric PBPK model possibly combined with pharmacodynamics (PBPK/PD model) may be a valuable aid in risk assessment.
Affiliation:
LBV
Publisher:
Rijksinstituut voor Volksgezondheid en Milieu RIVM
Issue Date:
28-Jun-2002
URI:
http://hdl.handle.net/10029/9261
Additional Links:
http://www.rivm.nl/bibliotheek/rapporten/623860011.html
Language:
en
Series/Report no.:
RIVM rapport 623860011
Appears in Collections:
RIVM reports - old archive

Full metadata record

DC FieldValue Language
dc.contributor.authorZwart LL deen_US
dc.contributor.authorHaenen HEMGen_US
dc.contributor.authorVersantvoort CHMen_US
dc.contributor.authorSips AJAMen_US
dc.date.accessioned2007-02-26T16:13:23Z-
dc.date.available2007-02-26T16:13:23Z-
dc.date.issued2002-06-28en_US
dc.identifier623860011en_US
dc.identifier.urihttp://hdl.handle.net/10029/9261-
dc.description.abstractBoth in the development of medicinal products as well as in risk assessment of other xenobiotics there is an increasing awareness that children should be considered as a special group. Children are exposed to other doses than adults and the pharmacokinetics and pharmacodynamics can be very different in children and adults. In general it can be concluded that the effects of age on pharmacokinetics are most pronounced during the first 6-12 months of life. Full adjustment of dosing or TDI's for pharmacokinetic differences can relatively easily be applied and should, to our opinion be seen as a first step in considering risk for the paediatric population. For risk assessment for drugs as well as for other xenobiotics, it seems to be essential that young animal models will be used for determining NOAELs, that are relevant for the paediatric population. The use of a paediatric PBPK model possibly combined with pharmacodynamics (PBPK/PD model) may be a valuable aid in risk assessment.en
dc.format.extent1411000 bytesen_US
dc.format.extent1444416 bytes-
dc.format.mimetypeapplication/pdf-
dc.language.isoenen_US
dc.publisherRijksinstituut voor Volksgezondheid en Milieu RIVMen_US
dc.relation.ispartofseriesRIVM rapport 623860011en_US
dc.relation.urlhttp://www.rivm.nl/bibliotheek/rapporten/623860011.htmlen_US
dc.subject.otherrisk assessmenten
dc.subject.otherpharmacokineticsen
dc.subject.otherchildrenen
dc.titlePharmacokinetics of ingested xenobiotics in children: A comparison with adultsen_US
dc.title.alternativeFarmacokinetiek van orale xenobiotica in kinderen: Een vergelijking met volwassenenen_US
dc.contributor.departmentLBVen_US
All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.